DALLAS – June 29, 2011 – After the recommendations of the FDA panel today regarding the cancer drug Avastin, Susan G. Komen for the Cure® remains steadfast in our support of breast cancer patients, and in support of research into new treatments as well as the development of biomarkers that will help us better understand who will benefit from certain treatments.
As it relates to the use of Avastin to treat women with metastatic breast cancer, our position remains that we want to be sure that women who are using Avastin, and for whom it is working, can continue to have access to it, that their insurers will continue to pay for it, and that the drug’s manufacturer (Genentech/Roche) continues making the drug available to women through its patient support programs, which we hope will be expanded. We are also urging Genentech/Roche to continue research on a biomarker for Avastin to determine which women will benefit from the drug.
We are supportive of the drug development process and hope that manufacturers will continue to develop medications for the treatment of metastatic breast cancer. We will only succeed in finding new treatments for cancer by bringing new drugs to the clinic.
As a patient advocate organization, we call on all stakeholders — government, private industry, academia and the nonprofit community — to invest in the development of biomarkers and new drugs, and to get the new technology and treatments to patients’ bedsides as safely and as quickly as possible.